Opus Genetics, Inc. (IRD) vs Relmada Therapeutics, Inc. (RLMD)
A side-by-side comparison of Opus Genetics, Inc. and Relmada Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IRD
Opus Genetics, Inc.
$4.38HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
RLMD
Relmada Therapeutics, Inc.
$3.28HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — IRD vs RLMD
growth of $100 · dividends reinvested · last 2yIRD +239.5% (+84.3%/yr)RLMD +296.6% (+99.1%/yr)RLMD compounded faster over this window
IRD RLMD
IRD vs RLMD: by the numbers
- •IRD is the larger company ($362M vs $344M market cap).
- •Both run net losses; RLMD's is the smaller (0.00% vs -1091.82% net margin).
Metrics side by side
Valuation
| Metric | IRD | RLMD |
|---|---|---|
| P/S ratio | 36.69 | N/A |
| P/B ratio | N/A | 1.67 |
Profitability
| Metric | IRD | RLMD |
|---|---|---|
| Gross margin | 99.87% | 0.00% |
| Operating margin | -271.90% | 0.00% |
| Net margin | -1091.82% | 0.00% |
| ROE | N/A | -29.98% |
| ROIC | -59.29% | -30.78% |
Growth (annualized)
| Metric | IRD | RLMD |
|---|---|---|
| Revenue CAGR (5Y) | 150.49% | N/A |
| Total return CAGR (5Y) | N/A | -7.68% |
Go deeper
Dig into the metrics
Opus Genetics ROERelmada Therapeutics ROEOpus Genetics operating marginRelmada Therapeutics operating marginOpus Genetics revenue growthRelmada Therapeutics revenue growthOpus Genetics free cash flowRelmada Therapeutics free cash flow
Opus Genetics & Relmada Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.